camptothecin has been researched along with somatostatin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Bazylevich, A; Bovina, A; Firer, MA; Gellerman, G; Hesin, A; Kostenich, G; Luboshits, G; Oron-Herman, M; Ragozin, E; Rubinek, T; Shekhter Zahavi, T; Sherman, MY; Tuchinsky, H; Wolf, I | 1 |
2 other study(ies) available for camptothecin and somatostatin
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
New somatostatin-drug conjugates for effective targeting pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Survival; Humans; Indoles; Kidney; Pancreatic Neoplasms; Peptides, Cyclic; Receptors, Somatostatin; Somatostatin; Stilbenes; Tissue Distribution; Xenograft Model Antitumor Assays | 2018 |